Research shows that puberty blockers, formally known as gonadotrophin-releasing hormone (GnRH) agonists, are generally considered reversible interventions. When these medications are stopped, the natural process of puberty typically resumes, allowing young people to develop according to their assigned sex at birth if that becomes their preferred path.

Clinical guidelines, including those from the World Professional Association for Transgender Health (WPATH), classify puberty blockers as the first step in a staged approach to gender-affirming care. These medications work by suppressing the hormones that drive pubertal development, effectively pausing rather than permanently altering the process. Bone density, height potential, and reproductive function are governed by sex hormones and any concerns are mitigated by the correct use of gender-affirming hormones in  trans youth. 

Research shows that prolonged use of blockers without hormones may have implications for bone density development and fertility, and the treatment plan must be taken as a whole.

The stepped approach of blockers to hormones is safe and allows families time to explore gender identity while maintaining future options. This interim period provides valuable space for young people to mature emotionally and cognitively before making decisions about partially reversible, or irreversible interventions. Healthcare providers emphasise the importance of comprehensive assessment and ongoing support throughout this process, recognising that each young person's journey is unique.